HOOK

In a report released on November 14, Andrew Berens from SVB Securities maintained a Buy rating on Hookipa Pharma (HOOK - Research Report), with a price target of $3.00. The company's shares closed yesterday at $1.17.Berens covers the Healthcare sector, focusing on stocks such as AVEO Pharma, Seagen, and Merus. According to TipRanks, Berens has an average return of 4.4% and a 46.55% success rate on recommended stocks. Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $7.60, which is a 549.57% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-buy-rating-for-hookipa-pharma-hook?utm_source=advfn.com&utm_medium=referral